Sugawara Yasuhiko, Makuuchi Masatoshi
Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
World J Gastroenterol. 2006 Jul 28;12(28):4461-5. doi: 10.3748/wjg.v12.i28.4461.
Living donor liver transplantation (LDLT) is an alternative therapeutic option for patients with end-stage hepatitis C virus (HCV) cirrhosis because of the cadaveric organ shortage. HCV infection is now a leading indication for LDLT among adults worldwide, and there is a worse prognosis with HCV recurrence. The antivirus strategy after transplantation, however, is currently under debate. Recent updates on the clinical and therapeutic aspects of living donor liver transplantation for HCV are discussed in the present review.
由于尸体器官短缺,活体肝移植(LDLT)是终末期丙型肝炎病毒(HCV)肝硬化患者的一种替代治疗选择。HCV感染目前是全球成年人LDLT的主要指征,且HCV复发预后较差。然而,移植后的抗病毒策略目前仍存在争议。本综述讨论了关于HCV活体肝移植临床和治疗方面的最新进展。